News

Net profit of Senores Pharmaceuticals rose 55.70% to Rs 30.72 crore in the quarter ended June 2026 as against Rs 19.73 crore during the previous quarter ended June 2025. Sales rose 38.30% to Rs 180.21 crore in the quarter ended June 2026 as against Rs 130.30 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales180.21130.30 38 OPM %29.8326.22 - PBDT49.4032.48 52 PBT39.4626.49 49 NP30.7219.73 56 Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 July 2026.

Net profit of Senores Pharmaceuticals rose 77.29% to Rs 31.61 crore in the quarter ended March 2026 as against Rs 17.83 crore during the previous quarter ended March 2025. Sales rose 53.39% to Rs 175.19 crore in the quarter ended March 2026 as against Rs 114.21 crore during the previous quarter ended March 2025.For the full year,net profit rose 96.99% to Rs 115.36 crore in the year ended March 2026 as against Rs 58.56 crore during the previous year ended March 2025. Sales rose 58.85% to Rs 632.63 crore in the year ended March 2026 as against Rs 398.25 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales175.19114.21 53 632.63398.25 59 OPM %27.1117.02 -26.6122.52 - PBDT56.7025.91 119 190.3587.41 118 PBT47.4020.68 129 159.1070.57 125 NP31.6117.83 77 115.3658.56 97 Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Senores Pharmaceuticals, Inc. (SPI), USA, a wholly owned subsidiary of Senores Pharmaceuticals, announced that it has successfully entered into a strategic partnership by executing a formal operating agreement on 02 April 2026. This agreement marks a decisive milestone in Senores` international expansion and its strategic entry into the U.S. government procurement market. The partnership has been formalized through the formation of a joint venture (JV) entity, namely Amerisyn, LLC (Amerisyn).The partnership represents a structural leap for Senores` US operations. Through the establishment of this JV framework, Senores is now strategically positioned to facilitate the supply of its high-quality product portfolio to the U.S. Federal Government, veterans affairs and military supply contracts and leverage specialized credentials to participate in long-term national contracts and government supply tenders.